Categories AlphaGraphs, Earnings, LATEST, Technology

Salesforce tops estimates; slides on weak Q3 outlook

Cloud computing company Salesforce.com (CRM) reported a 550% jump in earnings for the second quarter helped by gains on strategic investments. The top and bottom lines exceeded analysts’ expectations and the company raised its full-year 2019 guidance. The stock, which hit an all-time high today, is down about 1% in the extended hours after its third-quarter forecast fell below consensus.

Net income increased six times to $299 million or $0.39 per share. Excluding special items, earnings per share almost doubled to $0.71.

Revenue surged 27% year-over-year to $3.3 billion, due to benefits from clouds, industry segments, and geographies. Unearned revenue on the balance sheet as of July 31, 2018, increased 24% to $5.88 billion.

Looking into the third quarter of 2019, Salesforce expects profit in the range of $0.01 to $0.02 per share and adjusted earnings in the range of $0.49 to $0.50 per share. Revenues are anticipated to be in the range of $3.355 billion to $3.365 billion.

For the fiscal year 2019, the company raised its revenue outlook to a range of $13.125 billion to $13.175 billion from the prior estimate of $13.075 billion to $13.125 billion. GAAP EPS is now expected to be in the range of $0.97 to $0.99 and non-GAAP EPS is now predicted to be $2.50 to $2.52.

Salesforce second quarter 2019 earnings
Salesforce Q2 2019 Earnings Infographics

Salesforce’s all cloud service offerings contributed to its earnings, growing double digits, with Salesforce Platform reporting the highest growth of 54%. Subscription and support revenue saw a jump of 28%, surpassing projections.

Geographically, the Americas, which contributes 71% to the company’s revenue, jumped 25%, with Europe posting the highest growth of 35% for the quarter.

Shares of Salesforce ended Wednesday’s regular trading session up 1.18% at $154.80 on the NYSE. The stock had risen more than 64% for the past year.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top